# AnDiConBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/andiconbio

- Industry: Pharmaceuticals
- Headquarters: Jiaxing, China
- Total disclosed funding: $28M
- Latest round: Series A (Sep 16, 2025)
- Investors on record: 12

## About

Established in 2018 and based in Jiaxing, China, AnDiConBio is a biotech firm focusing on respiratory anti-infection and pain management. With a team of fewer than 50 employees, AnDiCon Bio is helmed by Dr. Wei Ping Jiang, who has an extensive background in the field. The company's core team comprises scientists with international perspectives and expertise in drug discovery and development. In June 2024, the company raised over CNY 200 million in a round of series A funding.

The company is dedicated to the research and development of novel drugs for respiratory infections. The company's portfolio includes treatments for influenza, COVID-19, and other respiratory diseases. Notable products include the oral anti-influenza drug ADC189 and the oral anti-COVID drug CN-2021, as well as Marduxanoxavir, a cap-dependent nucleic acid endonuclease inhibitor designed and developed in-house, which are designed to provide treatment options for patients with these conditions.

The company generates revenue by providing innovative pharmaceutical solutions and advancing its pipeline of anti-infection drugs.

The company will use the series A funding for the pre-clinical and clinical stage development of the core product pipeline, including accelerating the progress of pediatric clinical trials and commercialization of the self-developed new anti-influenza class 1 drug, Mardukhnosavir (code name ADC189), in tablets and granules.

## Funding rounds

- Series A, Sep 16, 2025 — Hangzhou Heda Industry Fund Investment, Hengdian Capital Management, Jiaxing Nanhu District New Venture Capital
- Series A, Jun 25, 2024, $28M — Simcere Pharmaceutical Group Limited, Cowin Capital, Golden China Fund, GSR United Capital, Jiaxing Nanhu New Venture Capital, Wenzhou Investment, Songze Capital, Jiarui Investment, Huajin Dadao Investment

## Investors

- Simcere Pharmaceutical Group Limited — Series A
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A
- Golden China Fund (https://capitalatlas.ai/funds/golden-china-fund) — Series A
- GSR United Capital (https://capitalatlas.ai/funds/gsr-united-capital) — Series A
- Jiaxing Nanhu New Venture Capital — Series A
- Wenzhou Investment (https://capitalatlas.ai/funds/wenzhou-investment) — Series A
- Songze Capital — Series A
- Jiarui Investment (https://capitalatlas.ai/funds/jiarui-investment) — Series A
- Huajin Dadao Investment — Series A
- Hangzhou Heda Industry Fund Investment — Series A
- Hengdian Capital Management — Series A
- Jiaxing Nanhu District New Venture Capital (https://capitalatlas.ai/funds/jiaxing-nanhu-district-new-venture-capital) — Series A